To test this, we used the well-validated KEAP1 inhibitors SFN, CDDO and KI-696, the BACH1 inhibitor TBE56 [28] and the dual KEAP1/BACH1 inhibitor CDDO-TFEA [27] in the lung cancer cell line H1299. This evidence concerns the gene KEAP1 and lung carcinoma.